Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors

Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant... Oncol Ther (2017) 5:171–180 DOI 10.1007/s40487-017-0052-4 ORIGINAL RESEARCH Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors . . . . . Lin Shen Yan Sun Jian-Ming Xu Carlos Linn Qiao Wang Li-Qiang Yang Shu-Kui Qin Received: April 25, 2017 / Published online: September 25, 2017 The Author(s) 2017. This article is an open access publication safety in Chinese patients is limited. Our ABSTRACT objective is to determine the efficacy and safety of sunitinib in Chinese patients with ima- Introduction: Sunitinib is approved in China tinib-resistant/intolerant GIST. for treatment of gastrointestinal stromal tumors Methods: An open-label, single-arm, multicen- (GIST), after disease progression on, or intoler- ter, phase IV study was performed in Chinese ance to, imatinib. However, available data from patients with imatinib-resistant/intolerant prospective clinical trials on its efficacy and GIST. Sunitinib was administered orally in 6-week cycles of 4 weeks on-treatment (50 mg Enhanced content To view enhanced content for this once daily) and 2 weeks off-treatment. The pri- article go to http://www.medengine.com/Redeem/ mary endpoint was progression-free survival 6C4CF060434CFC2F. (PFS). Tumors were assessed every 6 weeks for the first 24 weeks and every 12 weeks thereafter. C. Linn (&) 36 Floor, CITIC http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/phase-iv-study-of-sunitinib-in-chinese-patients-with-imatinib-ZXyQVCAsi6
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-017-0052-4
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2017) 5:171–180 DOI 10.1007/s40487-017-0052-4 ORIGINAL RESEARCH Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors . . . . . Lin Shen Yan Sun Jian-Ming Xu Carlos Linn Qiao Wang Li-Qiang Yang Shu-Kui Qin Received: April 25, 2017 / Published online: September 25, 2017 The Author(s) 2017. This article is an open access publication safety in Chinese patients is limited. Our ABSTRACT objective is to determine the efficacy and safety of sunitinib in Chinese patients with ima- Introduction: Sunitinib is approved in China tinib-resistant/intolerant GIST. for treatment of gastrointestinal stromal tumors Methods: An open-label, single-arm, multicen- (GIST), after disease progression on, or intoler- ter, phase IV study was performed in Chinese ance to, imatinib. However, available data from patients with imatinib-resistant/intolerant prospective clinical trials on its efficacy and GIST. Sunitinib was administered orally in 6-week cycles of 4 weeks on-treatment (50 mg Enhanced content To view enhanced content for this once daily) and 2 weeks off-treatment. The pri- article go to http://www.medengine.com/Redeem/ mary endpoint was progression-free survival 6C4CF060434CFC2F. (PFS). Tumors were assessed every 6 weeks for the first 24 weeks and every 12 weeks thereafter. C. Linn (&) 36 Floor, CITIC

Journal

Oncology and Therapy – Springer Journals

Published: Sep 25, 2017

References

  • Gastrointestinal stromal tumors
    Miettinen, M; Lasota, J
  • Gastrointestinal stromal tumors: what do we know now?
    Corless, CL
  • Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
    Hirota, S; Isozaki, K; Moriyama, Y; Hashimoto, K; Nishida, T; Ishiguro, S; Kawano, K; Hanada, M; Kurata, A; Takeda, M; Muhammad Tunio, G; Matsuzawa, Y; Kanakura, Y; Shinomura, Y; Kitamura, Y
  • Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract
    Hirota, S; Isozaki, K; Nishida, T; Kitamura, Y
  • PDGFRA activating mutations in gastrointestinal stromal tumors
    Heinrich, MC; Corless, CL; Duensing, A; McGreevey, L; Chen, CJ; Joseph, N; Singer, S; Griffith, DJ; Haley, A; Town, A; Demetri, GD; Fletcher, CD; Fletcher, JA
  • Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival
    DeMatteo, RP; Lewis, JJ; Leung, D; Mudan, SS; Woodruff, JM; Brennan, MF
  • Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  • Clinical management of gastrointestinal stromal tumors: before and after STI-571
    Dematteo, RP; Heinrich, MC; El-Rifai, WM; Demetri, G
  • Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
    Antonescu, CR; Besmer, P; Guo, T; Arkun, K; Hom, G; Koryotowski, B; Leversha, MA; Jeffrey, PD; Desantis, D; Singer, S; Brennan, MF; Maki, RG; DeMatteo, RP
  • Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    Zalcberg, JR; Verweij, J; Casali, PG; Le, Cesne A; Reichardt, P; Blay, JY; Schlemmer, M; Van, Glabbeke M; Brown, M; Judson, IR
  • Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, CD; Rankin, C; Demetri, GD; Ryan, CW; Mehren, M; Benjamin, RS; Raymond, AK; Bramwell, VH; Baker, LH; Maki, RG; Tanaka, M; Hecht, JR; Heinrich, MC; Fletcher, CD; Crowley, JJ; Borden, EC
  • SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    Abrams, TJ; Lee, LB; Murray, LJ; Pryer, NK; Cherrington, JM
  • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
    Mendel, DB; Laird, AD; Xin, X; Louie, SG; Christensen, JG; Li, G; Schreck, RE; Abrams, TJ; Ngai, TJ; Lee, LB; Murray, LJ; Carver, J; Chan, E; Moss, KG; Haznedar, JO; Sukbuntherng, J; Blake, RA; Sun, L; Tang, C; Miller, T; Shirazian, S; McMahon, G; Cherrington, JM
  • SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    Murray, LJ; Abrams, TJ; Long, KR; Ngai, TJ; Olson, LM; Hong, W; Keast, PK; Brassard, JA; O’Farrell, AM; Cherrington, JM; Pryer, NK
  • An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
    Kim, DW; Jo, YS; Jung, HS; Chung, HK; Song, JH; Park, KC; Park, SH; Hwang, JH; Rha, SY; Kweon, GR; Lee, SJ; Jo, KW; Shong, M
  • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    O’Farrell, AM; Abrams, TJ; Yuen, HA; Ngai, TJ; Louie, SG; Yee, KW; Wong, LM; Hong, W; Lee, LB; Town, A; Smolich, BD; Manning, WC; Murray, LJ; Heinrich, MC; Cherrington, JM
  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    Demetri, GD; Oosterom, AT; Garrett, CR; Blackstein, ME; Shah, MH; Verweij, J; McArthur, G; Judson, IR; Heinrich, MC; Morgan, JA; Desai, J; Fletcher, CD; George, S; Bello, CL; Huang, X; Baum, CM; Casali, PG
  • Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
    Demetri, GD; Garrett, CR; Schoffski, P; Shah, MH; Verweij, J; Leyvraz, S; Hurwitz, HI; Pousa, AL; Cesne, A; Goldstein, D; Paz-Ares, L; Blay, JY; McArthur, GA; Xu, QC; Huang, X; Harmon, CS; Tassell, V; Cohen, DP; Casali, PG
  • Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors
    Li, J; Gao, J; Hong, J; Shen, L
  • Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib
    Reichardt, P; Kang, YK; Rutkowski, P; Schuette, J; Rosen, LS; Seddon, B; Yalcin, S; Gelderblom, H; Williams, CC; Fumagalli, E; Biasco, G; Hurwitz, HI; Kaiser, PE; Fly, K; Matczak, E; Chen, L; Lechuga, MJ; Demetri, GD
  • A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
    Houk, BE; Bello, CL; Kang, D; Amantea, M
  • Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
    Yoon, DH; Ryu, MH; Ryoo, BY; Beck, M; Choi, DR; Cho, Y; Lee, JL; Chang, HM; Kim, TW; Kang, YK
  • Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
    Shirao, K; Nishida, T; Doi, T; Komatsu, Y; Muro, K; Li, Y; Ueda, E; Ohtsu, A
  • Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
    Heinrich, MC; Maki, RG; Corless, CL; Antonescu, CR; Harlow, A; Griffith, D; Town, A; McKinley, A; Ou, WB; Fletcher, JA; Fletcher, CD; Huang, X; Cohen, DP; Baum, CM; Demetri, GD
  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Debiec-Rychter, M; Sciot, R; Le, Cesne A; Schlemmer, M; Hohenberger, P; Oosterom, AT; Blay, JY; Leyvraz, S; Stul, M; Casali, PG; Zalcberg, J; Verweij, J; Glabbeke, M; Hagemeijer, A; Judson, I
  • Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
    Reichardt, P; Demetri, GD; Gelderblom, H; Rutkowski, P; Im, SA; Gupta, S; Kang, YK; Schoffski, P; Schuette, J; Soulieres, D; Blay, JY; Goldstein, D; Fly, K; Huang, X; Corsaro, M; Lechuga, MJ; Martini, JF; Heinrich, MC
  • The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure—one institution study
    Rutkowski, P; Bylina, E; Klimczak, A; Switaj, T; Falkowski, S; Kroc, J; Lugowska, I; Brzeskwiniewicz, M; Melerowicz, W; Osuch, C; Mierzejewska, E; Wasielewski, K; Wozniak, A; Grzesiakowska, U; Nowecki, ZI; Siedlecki, JA; Limon, J